Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits

Journal of Neuroimmunology

Volumn 255, Issue 1-2, 2013, Pages 85-91

  Jacek, Elzbieta ^a   Fallon, Brian A ^b   Chandra, Abhishek ^c   Crow, Mary K ^a   Wormser, Gary P ^d   Alaedini, Armin ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antibody; Borrelia burgdorferi; Cognitive dysfunction; IFN ; Lyme disease; Post Lyme disease syndrome

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BACTERIAL PROTEIN; CEFTRIAXONE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD ANALYSIS; CELL ASSAY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; IFI44 GENE; IFIT1 GENE; IMMUNOBLOTTING; IMMUNOMODULATION; IMMUNOSTIMULATION; LYME DISEASE; MALE; MEDICAL HISTORY; MEMORY DISORDER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; ANTIBODIES, BACTERIAL; BORRELIA BURGDORFERI; CEFTRIAXONE; CHRONIC DISEASE; COGNITION DISORDERS; FEMALE; HUMANS; INTERFERON-ALPHA; LYME DISEASE; MALE; MIDDLE AGED;

EID: 84872670683     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.011     Document Type: Article

References (43)

1. Aguero-Rosenfeld M.E., Wang G., Schwartz I., Wormser G.P. Diagnosis of lyme borreliosis. Clin. Microbiol. Rev. 2005, 18:484-509.
2. Akin E., McHugh G.L., Flavell R.A., Fikrig E., Steere A.C. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect. Immun. 1999, 67:173-181.
3. Alaedini A., Okamoto H., Briani C., Wollenberg K., Shill H.A., Bushara K.O., Sander H.W., Green P.H., Hallett M., Latov N. Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I. J. Immunol. 2007, 178:6590-6595.
4. Bratton R.L., Whiteside J.W., Hovan M.J., Engle R.L., Edwards F.D. Diagnosis and treatment of Lyme disease. Mayo Clin. Proc. 2008, 83:566-571.
5. Campbell I.L., Krucker T., Steffensen S., Akwa Y., Powell H.C., Lane T., Carr D.J., Gold L.H., Henriksen S.J., Siggins G.R. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999, 835:46-61.
6. CDC Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly. Rep. 1995, 44:590-591.
7. Chandra A., Wormser G.P., Klempner M.S., Trevino R.P., Crow M.K., Latov N., Alaedini A. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav. Immun. 2010, 6:1018-1024.
8. Chandra A., Latov N., Wormser G.P., Marques A.R., Alaedini A. Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clin. Immunol. 2011, 141:103-110.
9. Chandra A., Wormser G.P., Marques A.R., Latov N., Alaedini A. Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clin. Vaccine Immunol. 2011, 18:767-771.
10. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res. Ther. 2012, 12(Suppl. 1):S5.
11. Dafny N. Is interferon-alpha a neuromodulator?. Brain Res. Brain Res. Rev. 1998, 26:1-15.
12. D'Arcangelo G., Grassi F., Ragozzino D., Santoni A., Tancredi V., Eusebi F. Interferon inhibits synaptic potentiation in rat hippocampus. Brain Res. 1991, 564:245-248.
13. Das S., Shraga D., Gannon C., Lam T.T., Feng S., Brunet L.R., Telford S.R., Barthold S.W., Flavell R.A., Fikrig E. Characterization of a 30-kDa Borrelia burgdorferi substrate-binding protein homologue. Res. Microbiol. 1996, 147:739-751.
14. Fallon B.A., Keilp J.G., Corbera K.M., Petkova E., Britton C.B., Dwyer E., Slavov I., Cheng J., Dobkin J., Nelson D.R., Sackeim H.A. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008, 70:992-1003.
15. Feder H.M., Johnson B.J., O'Connell S., Shapiro E.D., Steere A.C., Wormser G.P., Agger W.A., Artsob H., Auwaerter P., Dumler J.S., Bakken J.S., Bockenstedt L.K., Green J., Dattwyler R.J., Munoz J., Nadelman R.B., Schwartz I., Draper T., McSweegan E., Halperin J.J., Klempner M.S., Krause P.J., Mead P., Morshed M., Porwancher R., Radolf J.D., Smith R.P., Sood S., Weinstein A., Wong S.J., Zemel L. A critical appraisal of "chronic Lyme disease". N. Engl. J. Med. 2007, 357:1422-1430.
16. Fritz-French C., Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. Cytokine Growth Factor Rev. 2012, 23:7-14.
17. Halperin J.J. Nervous system Lyme disease. Infect. Dis. Clin. North Am. 2008, 22:261-274.
18. Hayley S., Scharf J., Anisman H. Central administration of murine interferon-alpha induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: a mini-review and original experiments. Brain Behav. Immun. 2012, (Epub ahead of print).
19. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54:1906-1916.
20. Kalish R.A., Leong J.M., Steere A.C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect. Immun. 1993, 61:2774-2779.
21. Kariuki S.N., Crow M.K., Niewold T.B. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum. 2008, 58:2818-2823.
22. Klempner M.S., Hu L.T., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., Norton D., Levy L., Wall D., McCall J., Kosinski M., Weinstein A. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 2001, 345:85-92.
23. Lieb K., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Janssen G., Schaefer M. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur. Psychiatry 2006, 21:204-210.
24. Ma B., Christen B., Leung D., Vigo-Pelfrey C. Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi. J. Clin. Microbiol. 1992, 30:370-376.
25. Marques A. Chronic Lyme disease: a review. Infect. Dis. Clin. North Am. 2008, 22:341-360.
26. Mendoza-Fernandez V., Andrew R.D., Barajas-Lopez C. Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus. Brain Res. 2000, 885:14-24.
27. Miller J.C., Ma Y., Bian J., Sheehan K.C., Zachary J.F., Weis J.H., Schreiber R.D., Weis J.J. A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice. J. Immunol. 2008, 181:8492-8503.
28. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8:492-502.
29. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
30. Nowalk A.J., Gilmore R.D., Carroll J.A. Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 2006, 74:3864-3873.
31. Pothlichet J., Niewold T.B., Vitour D., Solhonne B., Crow M.K., Si-Tahar M. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med. 2011, 3:142-152.
32. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
33. Salazar J.C., Pope C.D., Sellati T.J., Feder H.M., Kiely T.G., Dardick K.R., Buckman R.L., Moore M.W., Caimano M.J., Pope J.G., Krause P.J., Radolf J.D. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J. Immunol. 2003, 171:2660-2670.
34. Sas A.R., Bimonte-Nelson H.A., Tyor W.R. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 2007, 21:2151-2159.
35. Sas A.R., Bimonte-Nelson H., Smothers C.T., Woodward J., Tyor W.R. Interferon-alpha causes neuronal dysfunction in encephalitis. J. Neurosci. 2009, 29:3948-3955.
36. Somers E.C., Zhao W., Lewis E.E., Wang L., Wing J.J., Sundaram B., Kazerooni E.A., McCune W.J., Kaplan M.J. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7:e37000.
37. Stanek G., Strle F. Lyme borreliosis. Lancet 2003, 362:1639-1647.
38. Stanek G., Strle F. Lyme disease: European perspective. Infect. Dis. Clin. North Am. 2008, 22:327-339.
39. Steere A.C. Lyme disease. N. Engl. J. Med. 2001, 345:115-125.
40. Strle K., Jones K.L., Drouin E.E., Li X., Steere A.C. Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am. J. Pathol. 2011, 178:2726-2739.
41. Wechsler D. Wechsler Memory Scale 1997, The Psychological Corporation, San Antonio.
42. Wormser G.P., Liveris D., Nowakowski J., Nadelman R.B., Cavaliere L.F., McKenna D., Holmgren D., Schwartz I. Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease. J. Infect. Dis. 1999, 180:720-725.
43. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., Krause P.J., Bakken J.S., Strle F., Stanek G., Bockenstedt L., Fish D., Dumler J.S., Nadelman R.B. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 43:1089-1134.